Sustained anti-adherence activity of taurolidine (Taurolin) and noxythiolin (Noxyflex S) solutions.
Taurolidine (2% w/v) and noxythiolin (1% w/v and 2.5% w/v) solutions inhibit the adherence in-vitro of Escherichia coli and Staphylococcus aureus to human epithelial and fibroblast cells. This effect, demonstrable after 30 min exposure of cells to test drugs, persists after removal of the active compound. Significantly reduced adherence of bacteria is apparent for 5 h after taurolidine treatment and for 6 h after treatment with 2.5% noxythiolin. Anti-adherence activity of taurolidine and noxythiolin may contribute to the observed clinical efficacy of these agents.
Blenkharn
J I
JI
Department of Bacteriology, Royal Postgraduate Medical School, Hammersmith Hospital, London, UK.
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001646:Bile / Q000166:cytology; D002448:Cell Adhesion / Q000187:drug effects*; D004848:Epithelium / Q000187:drug effects / Q000502:physiology; D042882:Gallstones / Q000473:pathology / Q000601:surgery; D006801:Humans; D009677:Noxythiolin / Q000494:pharmacology*; D012016:Reference Values; D012996:Solutions; D013654:Taurine / Q000031:analogs & derivatives*; D013829:Thiadiazines / Q000494:pharmacology*; D013843:Thiazines / Q000494:pharmacology*; D013890:Thiourea / Q000031:analogs & derivatives*; D014556:Urine / Q000166:cytology
D000900:Anti-Bacterial Agents; D012996:Solutions; D013829:Thiadiazines; D013843:Thiazines; D013654:Taurine; D009677:Noxythiolin; C012566:taurolidine; D013890:Thiourea